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ABSTRACT
STUDIES TOWARD SYNTHESIS OF A PROTECTED DERIVATIVE OF LENDURACIDIDINE VIA C-H ACTIVATION
BY
IRAM MUZAFFAR
University of New Hampshire, May 2022

Over the years bacteria have developed resistance against antibiotics. Overuse and
misuse of antibiotics is one of the main reasons of this increased bacterial resistance. A
recently discovered peptide antibiotic known as teixobactin has shown potent activity
against Gram-positive bacteria including methicillin-resistant Staphylococcus. aureus
(MRSA), Mycobacterium tuberculosis, and vancomycin-resistant enterococci, (VRE). The
structure of teixobactin consists of several uncommon amino acids including D-aminoacids and L-allo-enduracididine. L-allo-Enduracididine is a unique amino acid residue
consisting of a 5-membered guanidine ring, which offers a great challenge for its synthesis.
Most of the reported syntheses of L-allo-enduracididine are lengthy and consist of a lack
of stereoselectivity and overall low yields, which stresses the need to develop a more
efficient synthetic route to enduracididine using readily available reagents.
A synthetic strategy was proposed to construct the 5-membered cyclic guanidine
structure using a C-H amination reaction catalyzed by Rh2(esp)2 as the key step. For this
purpose, attempts to synthesize various arginine derivatives bearing a 2,2,2trichloroethoxysulfonyl- (Tces-) protected guanidine were conducted by condensing
isothiourea 21 with different derivatives of L-ornithine.

xi

First, 2,2,2-trichloroethylsulfamate (24) was synthesized from chlorosulfonyl
isocyanate

(CSI)

with

57%

yield.

S,S-Dimethyl-N-(2,2,2-

trichloroethoxysulfonyl)carbonimidodithionate (25) was made from 24 in 89% yield,
which

was

consequently

converted

to

S-Methyl-N-(2,2,2-

trichloroethoxysulfonyl)isothiourea (21) in 94 % yield. Ester derivatives of L-ornithine
were

synthesized,

including

N-(δ-tert-butoxycarbonyl)-N-(α-([fluoren-9-

yl]methoxy)carbonyl)-L-ornithine methyl ester (28)

in 80% yield, and N-(δ-tert-

butoxycarbonyl)-N-(α-([fluoren-9-yl]methoxy)carbonyl-L-ornithine allyl ester (34) in 93
% yield. Removal of the Boc protecting group was followed by the attempted coupling of
the L-ornithine derivatives with 21, which was unsuccessful and instead gave product
whose NMR data was consistent with the formation of a lactam (38) resulting from reaction
of the -amino group with the ester. C-H amination was attempted on L-Ornithine, N2[(9H-fluoren-9-ylmethoxy)carbonyl]-N5-[imino[[(4methylphenyl)sulfonyl]amino]methyl], methyl ester (41) by using Rh2(esp)2 which gave a
complex mixture of compounds. The presented strategy could be used in the future for
synthesizing protected arginine derivatives by modifications in the starting molecules.
These would serve as substrates for making nitrogen-based heterocyclic compounds via CH amination by exploring different Rh based catalysts.

xii

Chapter 1: Introduction to antibacterial resistance and Teixobactin
Bacterial Infections: Threat to Human Health and Global economy
Despite the fact that pharmaceutical industries and global health systems have
made significant improvements in finding cures and advancement in research and
development of drugs, bacterial infections and outbreaks have not only destroyed human
health, but have also severely affected the global economy.1 At the present time we
continue to face diseases related to old microorganisms e.g., plague which was first
encountered by humans centuries ago, and new microorganisms like human
immunodeficiency virus (HIV), which has developed various mutations over the course of
years.1 Some infectious diseases, for example tuberculosis (TB) and malaria, are prevalent
in various areas, imposing extensive but constant complications to global health. Infections
like influenza vary in rifeness and intensity, inflicting chaos in the developing and
developed worlds alike. According to the World Health Organization (WHO), in 2012,
there were nearly 450 000 new globally reported cases for multidrug-resistant tuberculosis
(MDR-TB), and furthermore, extensively drug-resistant tuberculosis (XDR-TB) has been
identified in 92 countries.2 In May 2016, the World Health Organization (WHO) issued a
list of epidemic-potential disease priorities requiring urgent R&D attention.3

Antibiotics targets and mode of action
Research has shown that there are 5 main antibiotic targets in bacteria. (Figure 1).
The bacterial cell wall that provides strength is made up mainly of peptidoglycan (PG), a
mesh of polysaccharide strands that are cross-linked by peptides. This cell wall is thick in
gram-positive bacteria but thin in gram-negative. β-lactam-containing penicillins and
1

cephalosporins kill the bacteria by binding to the active sites of transpeptidases which are
also known as penicillin-binding proteins (PBPs)4. By occupying the enzyme active sites,
these antibiotics block the normal crosslinking of peptide chains in the peptidoglycan layer
which make the cell wall weaker in strength and vulnerable to lysis due to changes in
osmotic pressure. Eukaryotic cells do not have a cell wall of peptidoglycan, which makes
it possible for these antibiotics to attack bacterial cells selectively.

Figure 1: Main targets of antibiotics in bacteria and mechanisms of antibiotic
resistance.5
Protein synthesis is carried out by ribosomes where they convert the mRNA into
the subsequent polypeptide chain6. The process is generally divided into four steps such as
initiation, elongation, termination, and recycling. RNA and protein synthesis in bacteria is

2

significantly different from eukaryotes. Antibiotics take advantage of this and target the
ribosomes of bacteria selectively without affecting the eukaryotic cell.4 The antibiotics
involved in this mechanism are macrolides of erythromycin class, the oxazolidinones, the
tetracyclines and the aminoglycosides (Figure 2).

Figure 2: The mechanism of protein synthesis and antibacterial targets5

3

Bacterial strategies of development of resistance against antibiotics
The discovery of antibiotics more than 80 years ago lead to a period of drug
revolution and implementation in human, animal health and agriculture. These discoveries,
however, were soon encountered with challenges posed by the emergence of resistant
microorganisms.7,8 It has been predicted that antimicrobial resistance (AMR) will be liable
for more deaths than cancer by 2050.9 Studies have also shown that patients who have
infections caused by drug resistant bacteria are mostly at higher risk of death, and more
health-care resources are consumed on them than those patients who are infected with a
nonresistant strain.2
Overuse and misuse of antibiotics is one of the main reasons of increased bacterial
resistance against to antibiotics. Alexander Fleming, in an interview in 1945, warned that
the overuse of penicillin would lead to an increase of bacterial resistance.13
Improper/unnecessary antibiotic prescription by physicians, particularly for viral upper
respiratory tract infections is very common.10 Respiratory tract infections are among the
most common reasons for which people seek medical support in the United States, and they
are responsible for up to 75% of total antibiotic prescriptions each year.11 The causes of
misuse and overuse of antibiotics, which is an alarming situation throughout the world, are
more complex and need to be addressed.12,13 But in 2009, more than 3 million kg of
antibiotics were given to human patients in the United States alone while in 2010, 13
million kg were processed to animals.14
Studies have shown that bacteria develop resistance against an antibiotic within
months to years after its widespread human therapeutic use.1515 Four main strategies are
used by bacteria to resist the antibiotics. The first strategy prevents the drug molecules
4

from entering the cell. Porin channels are the proteins present in the outer membranes of
gram-negative bacteria which allow the entry of antibiotics. Modifications in these
channels induces resistance so that drug molecules cannot enter the bacteria. This type of
strategy is rare and mainly observed against β-lactam antibiotics (Figure 3).
The second strategy involves the expulsion of antibiotics through efflux pumps.
Most of the antibiotics need to enter the cytoplasm through the cell membrane and attack
their specific targets. For example, ribosomes responsible for protein synthesis are in the
cytoplasm, therefore antibiotics which inhibit protein synthesis must pass through the cell
membrane and congregate in high enough concentration to effectively block the protein
synthesis. However, many bacteria including both Gram-positive and Gram-negative,
overproduce membrane associated proteins which act as efflux pumps and eject those
antibiotics which enter the cell, thus maintaining their concentration at lower levels which
cause minimal damage to the bacterial machinery. This mechanism of resistance has been
observed in many classes of bacteria, especially in staphylococci which are resistant to the
erythromycin class of macrolide antibiotics.16
Degradation or modification of drug molecules is the third strategy used by
bacteria to nullify the effect of antibiotics. In addition to the hydrolytic deactivation of the
β-lactam ring in the penicillins by using hydrolytic enzyme -lactamase, the structure of
antibiotics is neutralized by deactivating enzymes in bacteria. The aminoglycosides are the
main target of this bacterial combat strategy as they do not contain any group like β-lactam
which can be degraded hydrolytically. The chemical structure of aminoglycosides is
modified when enzymes embellish the outside of these antibiotics with different types of
chemical substituents like PO3 groups, and acetyl groups.17 Due to the addition of these
5

groups, aminoglycosides have significant lower affinity for RNA, hence this disrupts the
binding of the antibiotic to the RNA target in the ribosome and the antibiotic becomes inept
for inhibiting the protein production machinery of bacteria.

Figure 3: Structural representation of antibiotics of β-lactam class 6

A fourth mechanism involves modification or masking of the target in resistant
bacteria. For example, mono or demethylation of a specific adenine residue in the peptidyl
transferase loop of the 23S RNA component of the ribosome has resulted in resistant strains
of bacteria toward the erythromycin class of antibiotics.4 The methyl transferase enzyme
Erm is responsible for this modification.18 This modification does not inhibit protein
biosynthesis, but does lower the affinity of the erythromycin class of drugs for the RNA.
All the mechanisms of resistance development described above pose a great
challenge in longevity and effectiveness of antibiotics. In addition to synthesizing new
classes of antibiotics, various new targets for antibiotics are being explored. There is a
necessity to expand the search and develop new antibiotics to counter the increased
bacterial resistance.

6

Teixobactin:
In early 2015, a new antibiotic named teixobactin was reported19 (Figure 4).
Teixobactin, a non-ribosomal depsipeptide antibiotic synthesized by the Gram-negative
bacterium Eleftheria terrae was isolated by using the multichannel device, the isolation
chip (iChip).20 The structure of teixobactin consists of several uncommon amino acids
including D-amino-acids and L-allo-enduracididine (Figure 4), where the last four residues
forms a ring structure. Teixobactin has drawn significant attention from the scientific
community amongst the recent classes of antibiotics unearthed from nature, as it has shown
potent activity against Gram-positive bacteria including methicillin-resistant S. aureus
(MRSA), Mycobacterium tuberculosis, and vancomycin-resistant enterococci, (VRE).21

Figure 4: Structure of Teixobactin and enduracididine 22
In vitro studies have shown two distinctive modes of action of teixobactin.20 It
inhibits bacterial cell wall synthesis by binding lipid II, a precursor in the biosynthesis of
peptidoglycan and lipid III, a precursor for the biosynthesis of wall teichoic acid.21 (Figure
5).

7

Development of resistance against teixobactin is difficult because of this attack
on non-proteinogenic molecules i.e. Lipid II and III, whose modification would
significantly impair cell wall synthesis.21,23,24.

Figure 5: proposed target of teixobactin in bacterial 25

A limited amount of lipid II is synthesized at a time by the bacteria via lipid II
biosynthetic cycle,26 which makes it a limiting factor for bacterial cell wall synthesis,
making it a very attractive target for antibiotic development. Teixobactin inhibits genetic
modification of its drug target in pathogenic bacteria, by binding and trapping distinct, latestage cell wall intermediates instead of protein targets.20
In addition to inhibition of peptidoglycan synthesis, teixobactin performs an
exceptional bactericidal activity by collaborative inhibition of wall teichoic acid synthesis
by binding to lipid III which is a key building block in the synthesis of wall teichoic acid.27
Due to binding of teixobactin to lipid III, binding of lytic enzymes (autolysins) is reduced,
which results in cleavage of peptidoglycan and ultimately bacterial cell death.27

8

Teixobactin has not been found effective against Gram-negative bacteria, mainly
because of the outer membrane barrier present in these bacteria, as evidenced that
teixobactin has shown effective bactericidal response against Escherichia coli asmB1,
which

is

an

outer

membrane

deficient

strain.20.

However,

this

newly

discovered antibiotic demonstrates great potential for further development as a drug for
treating infections caused by Gram-positive bacteria.
Surprisingly, no teixobactin-resistant mutants of Staphylococcus aureus or
Mycobacterium tuberculosis emerged when the bacteria were treated with sub-MIC levels
of teixobactin over a 27 day dosage period,28 again highlighting the fact that the molecular
target of teixobactin is not an endogenous protein. For the synthesis of teixobactin it is
essential to gain access to all the amino acid residues in sufficient quantity and high-level
stereochemical purity. A unique amino acid residue found in teixobactin is L-alloenduracididine, which presents a great challenge toward its synthesis.
L-allo-enduracididine belongs to the class of 6 rare amino acids that consist of a
unique five-membered cyclic guanidine moiety (Figure 6). L-Enduracididine (1) and Dallo-enduracididine (4) were the first ones from this class to be identified as residues found
in depsipeptide antibiotics.29

9

Figure 6: Structures of the amino acids of Enduracidine family29

Enduracididine (1) was later isolated as free from the seeds of the legume
Lonchocarpus sericeus.29 L-allo-enduracididine (3) is part of the structure of the antibiotic
teixobactin. Researchers have synthesized analogues of teixobactin and it has been reported
after biological testing that (3) is important for the antibacterial activity of Teixobactin.30
When the enduracididine residue was substituted for L-arginine, the activity of Teixobactin
was observed to decrease 10-fold.31 The activity was entirely lost when three of the four
D-amino acids of the analogue were substituted for their L-counterparts.32
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Chapter 2: Overall research goal
Our goal is to synthesize L-allo-enduracididine by developing a synthetic scheme
consisting of fewer steps than most of the proposed synthetic methodologies at present,
giving the high yield of product. One of the biggest challenges in synthesis of
enduracididine is to create a stereoselective center at C4. (Figure 3). Many syntheses of
enduracididine have been reported, and the discovery of teixobactin has increased the
interest in synthesis of this amino acid residue. However, most of the reported synthetic
approaches consist of multiple steps and low yields. For instance, the first reported
stereoselective synthesis of enduracididine by Shiba et al.33 utilized hydrogenation of a
histidine derivative (8) to generate the C4 center and afforded lactam (9) which upon
treatment with guanylating agent (10) gave L-enduracididine (12) as a mixture of
diastereomers. (Scheme 1).

Scheme 1: Synthesis of enduracididine 12 by Shiba et al.29,33

After that Dauban and Dodd reported a synthesis of protected enduracididine by
an aziridine ring opening using sodium azide as a key approach to create the nitrogen
center. Two diastereomers (15) and (16) were isolated in the aziridination reaction in an
overall yield of 21 %.34 these two diastereomers afforded the protected enantiomers of Lenduracididine (18) and L-allo-enduracididine (19). (Scheme 2).
11

Scheme 2: Synthesis of protected enduracididine 18 and 19 by Dodd et al.29,34

The shortcomings of these synthetic methodologies are length of proposed
schemes, lack of stereoselectivity and overall lower yield which stresses the need to
develop a more efficient synthesis of enduracididine using readily available reagents. We
intend to take advantage of C-H amination as the key step to construct the cyclic guanidine
structure found in the final product. C-H amination would be achieved by using a Rh
catalyst reported by Espino et al. at Stanford University.35 (Figure 7).

12

Figure 7: Rh2(esp)2catalyst reported by Espino et al.35

Research showed that Rh2(esp)2, a tethereddicarboxylate-derived complex proved
to be superior in catalytic activity for intramolecular C-H activation with sulfamate,
sulfamide, and urea substrates compared to simple dirhodium tetracarboxylate complexes
(i.e., Rh2(OAc)4, Rh2(O2CCPh3)4).
Later,

Kim

at

el.36

reported

efficient

C−H

amination

of

N-

trichloroethoxysulfonyl-protected ureas and guanidines to form 5- and 6-membered rings
by using Rh2(esp)2. The success of these reactions was dependent on the presence of the
electron-withdrawing 2,2,2-trichloroethoxysulfonyl (Tces) protecting group. They
demonstrated successful oxidative cyclization of various N-Tces alkylguanidine substrates.
(Figure 8). In this intramolecular amination reaction, first Rh2-nitrene intermediate (c) is
generated from (b) which then undergoes subsequent C-H insertion process. The Rh2-
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nitrene is regard as a key catalytic intermediate in this reaction and is responsible for NRgroup insertion into the C-H bond, forming 5 membered cyclic product (d)

Figure 8: C-H insertion of Tces protected Alkylguanidine substrates reported by
kim at el.36

The overall synthetic plan (Scheme 3) is comprised of first synthesizing
guanidinylation product (22) by a coupling reaction between isothiourea (21) and Fmocprotected L-ornithine (20) in the presence of mercury (II) chloride and N,NDiisopropylethylamine (i-Pr2NEt). Cyclization to the five-membered ring can be done by
14

C-H amination of (22) in the presence of a Rh2(esp)2 catalyst, giving the target molecule
(23).

Scheme 3: Proposed synthetic route to 23.

15

Chapter 3: Results and Discussion
Synthesis of imidodithionate (25) and isothiourea (21)
Synthesis of target molecule 23 was divided into two parts. In the first part
isothioure 21 was synthesized and in second part L-ornithine was protected with various
ester derivatives. The synthesis of 21 begins by first synthesizing imidodithionate 25 from
trichloroethylsulfamate 24 (scheme 4).36

Scheme 4: Synthesis of imidodithionate 2535,36

The reaction takes place firstly by nucleophilic attack of the amino group of 24
toward CS2, followed by the methylation of each thiolate group by the strong methylating
agent Me2SO4.The first rection to form 25 was quite challenging due to many factors
involving in the synthesis like preparing very concentrated NaOH solution, purification,
and removal of DMF from the product.
The literature used recrystallization for purification as no solid product was
obtained purification was done by column chromatography which gave the pure product
25 as white solid with significant higher yield of 84% compared to 55% literature yield.
Table 1: NaOH concentrations and effect on the reaction
Conditions for NaOH

Equivalence

Result

10 M, 0 °C to room

2.8

No

temp

Reaction
16

15 M, 0 °C to room

2

17% yield

1.4

84%

temp
20 M, 0 °C to room
temp

Product 21 was synthesized from 25 by amination by using methanolic ammonia.
(Scheme 5). The reaction proceeds when lone pair on NH3 attack electrophilic carbon
center of imididithionate (25), the C=N bond breaks to form a tetrahedral intermediate,
then re-forms to lose MeS-. removing methanethiol (MeSH) as biproduct.
Purification by column chromatography gave the product as white solid with 94%
yield. 1H NMR spectroscopy helped to confirm the identity of pure product 21, as a peak
at δ 2.48 ppm corresponding to 3 protons indicates the presence of one MeS group instead
of two.

Scheme 5: Formation of Isothiourea 21 from 2536

The starting molecule trichloroethylsulfamate 24 used in this reaction was initially
purchased, but because of its high cost, it was decided to synthesize this by using literature
reaction reported by Guthikonda et al.37 (Scheme 6). In this reaction, chlorosulfonyl
isocyanate (CSI) 26 reacts with formic acid first to generate sulfamoyl chloride as a white
solid along with CO and CO2 as biproducts. (Scheme 6).
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Trichloroethanol was added which reacts with sulfamoyl to give the final product
24. Dimethylacetamide (DMA) was used as polar solvent. 1HNMR showed a pure product
was obtained, and all NMR data was aligned with the literature.

Scheme 6: Synthesis of trichloethylsulfamate 2437

Synthesis of protected L-ornithine (28)
Protection of the carboxylic acid of 27 is needed for this L-ornithine derivative to
later undergo a smooth coupling reaction with isothiourea 21 to form the guanidinylated
product.

Scheme 7: : Protection of carboxyl group as its methyl ester by DCC-mediated
coupling38
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The carboxylic acid group was protected by using Steglich esterification, a mild
reaction which uses dicyclohexylcarbodiimide (DCC) as a coupling reagent and 4dimethylaminopyridine (DMAP) as a catalyst. (Scheme 7).
In this reaction, DMAP first extracts the proton of the carboxylic acid, and the
resulting carboxylate anion then attacks the electrophilic carbon of DCC, forming an Oacylisourea intermediate (Scheme 8). Strong nucleophiles such as amines do not need
additives such as DMAP because they react readily with the O-acylisourea to form amides.
However, an alcohol is a relatively weaker nucleophile and may not add to the activated
carboxylic acid, which allows competing 1,3-rearrangement of the O-acylisourea to occur
and give the stable side product N-acylurea.

Scheme 8 : Reaction mechanism of a general Steglich Esterification:
19

However, DMAP is a stronger nucleophile than the alcohol, so it reacts with
the O-acylisourea forming a reactive amide. The resultant intermediate cannot rearrange to
form side products but reacts quickly with alcohols (Scheme 8). In this way DMAP acts as
an acyl transfer reagent, and consequent reaction with the alcohol gives the ester final
product. DMAP is regenerated at the end and hence acts as a catalyst.

Carboxylic acid esterification of Fmoc and Boc protected L-ornithine 27 was
achieved by using methanol in this reaction. Complete purified product was obtained by
column chromatography with 80% yield. A singlet at δ 3.62 ppm in the 1H NMR spectrum
corresponds to the three protons of the OCH3 group and the 13C NMR spectrum indicates
the carbon of the OCH3 at δ 52.2 ppm, confirming the desired product was obtained.

Removal of Boc group by TFA to synthesize (29).
Deprotection of Boc-protected -amino group of 28 is needed to make the amine
available for coupling with isothiourea 21. Trifluoracetic acid (TFA) was chosen as a
deprotecting agent because it will only hydrolyze the Boc group without affecting the Fmoc
group, resulting in formation of product 29 (Scheme 9)38.

Scheme 9: Deprotection of δ-amino group of 28 to give product 2938
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Mechanistically, this reaction first involves protonation of the carbonyl oxygen
of the Boc group by TFA, which results in loss of a t-butyl carbocation in the second step.
The resulting molecule, a carbamic acid, undergoes proton transfer followed by
decarboxylation to give the deprotected amine, which is converted to its TFA salt under
the acidic conditions (Scheme 10). CO2 evolution was observed as white fumes during the
reaction. The1H NMR data align with the literature. Complete removal of singlet at δ 1.38
ppm corresponding to 9 protons of Boc group confirms that the desired product 29 was
obtained.

Scheme 10: General mechanism of Boc removal with TFA
All the biproducts of this reaction are volatile i.e., CO2 and isobutylene which is
formed from deprotonation of the t-butyl carbocation, which has boiling point -7 ˚C. 29
was obtained as a yellowish sticky residue with quantitative yield. 1H NMR showed that
the pure product had been isolated but TFA was difficult to remove completely. So, it was
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decided to use the 29 for next step without further purification as it is very polar and would
stick to the silica on column.

Deprotection of Boc group by HCl in dioxane to form (30)
Due to the difficulty in removing excess TFA from product 29, an alternative
method of Boc removal was explored. In this reaction 4 M HCl in dioxane was used for
the acid hydrolysis of the Boc group (Scheme 11).39 Moreover, the literature procedure
used by Spinnler et al.38 also showed that the HCl salt of L-ornithine gave better yields
when coupled with a guanidinylating reagent that is similar in structure to reagent 21 used
in our synthesis.

Scheme 11: Deprotection of -amino group of 28 by HCl in dioxane39
Boc removal with HCl follows the same mechanism as TFA-catalyzed
deprotection in which protonation of the carbonyl of the t-butyl carbamate takes place in
the first step, with consequent generation of a t-butyl cation and CO2 gas. Product obtained
was the HCl salt 30 which is very polar.
The final yield was 98% and disappearance of the singlet at δ 1.38 ppm on 1H
NMR corresponding to the t-butyl group confirmed removal of the Boc group.
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Attempted synthesis of guanidinylation product 31 from L-ornithine methyl
ester 29
Synthesis of arginine derivative 31 was first attempted by following the procedure
reported by Kim et al.36(Scheme 12). They reacted a primary amine and isothiourea
substrate 21 in a sealed thick-walled tube with water as the solvent. By heating the reaction
mixture at 100 ˚C for 4 hours, they reported several guanidinylated substrates in very good
yields.

Scheme 12: Attempted synthesis of Tces guanidine 3136

However, the reaction between 21 and 29 did not occur (Scheme 12) and only
starting materials were recovered. This result isn’t surprising as unlike the literature
procedure which employs a free amine as the starting material, compound 29 is an
ammonium salt and is not nucleophilic enough to attack the electrophilic carbon center of
21. Following the failure of this reaction another method of coupling was tried, reported
by Spinnler et al.38
Spinnler and coworkers developed a synthetic methodology in which they reacted
the HCl or TFA salt of Fmoc-protected L-ornithine 20 with guanidinylating reagent 32 to
give a guanidine product 33.38 (Scheme 13). salt 20 was reacted with 32 in the presence of
N,N-Diisopropylethylamine (i-Pr2NEt) as base and HgCl2, which acts as a Lewis acid to
coordinate the sulfur of the MeS group and enhance its leaving group ability.
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Scheme 13: Synthesis of Guanidine product 33 by Spinnler et al.38

Following this procedure, first, TFA salt 29 was reacted with guanidinylating
reagent 21 and then HCl salt 30 was reacted with 21. (Scheme 14). But in both cases
guanidinylated product 31 was not obtained. Instead, a side protect was observed, the 1H
NMR showed that the protecting group methyl ester was cleaved, however, two protons on
Tces of 21 were present. 1H NMR also indicated that MeS was removed from the 21. Which
indicates that some reaction is taking place but it’s not giving the desired product.

Scheme 14: Attempted synthesis of 31 using conditions reported by Spinnler et
al.38
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Synthesis of protected L-ornithine (34) and removal of Boc group
Spinnler et al38 have reported that using an L-ornithine derivative protected as an
allyl ester for this coupling reaction gives good yields and lesser biproducts compared to
methyl ester proteced derivative. So allyl alcohol was allowed to react with 27 in the
presence of DCC and DMAP (Scheme 15) to give corresponding allyl ester 34. The
mechanism of this reaction is the same as for the methyl ester synthesis described in
Scheme 5.

Scheme 15: Protection of carboxyl group as an allyl ester using DCC and
DMAP.38

The reaction gave product 34 with relatively higher yield of 93% compared to
methyl ester product 28, which was obtained in 80% yield (Scheme 7). 1H NMR and 13C
NMR spectroscopy confirmed the identity and purity of 34 and data align with the
literature.
Peaks at δ 4.5 ppm corresponding to two protons, two peaks at δ 5.2 and 5.3 ppm
each representing to one proton and a multiplet at δ 5.8 ppm showing one proton in the 1H
NMR spectrum corresponds to the allyl group, confirming the desired product was
obtained.
Removal of the Boc group was carried out as previously described, using either
TFA or 4 M HCl in dioxane (Scheme 16). The deprotection with TFA was successful to
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give product 35, however, excess TFA proved challenging to remove, with its presence
confirmed by 13C NMR spectroscopy (Figure 9).

Scheme 16: Deprotection of Boc-protected -amino group of 34 with TFA to
form 35 and with HCl to form 3638,39

HCl-catalyzed deprotection gave the white solid product 36 (Scheme 16) in 78%
yield and purity of the product was confirmed by 1H NMR and 13C NMR. However, traces
of dioxane remained a challenge to remove from the product.

26

Figure 9: 13C NMR spectra (176 MHz, DMSO-d6)) of the HCl salt 36 (A) and the
TFA salt 35 (B).

Attempted synthesis of arginine derivative 37 from L-ornithine allyl ester
The reactions between TFA salt 35 and isothiourea 21 and ammonium salt 36
and isothiourea 21 were conducted by following the conditions described by Spinnler et
al.38 ( Scheme 17). Although starting material 21 was consumed under the reaction
conditions and 1H NMR spectroscopic analysis indicated the Tces-protected functional
group was incorporated into the product, the allyl protecting group was removed.
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Scheme 17: Attempted synthesis of 37 from L-ornithine allyl ester 35 and 36

By looking at the mechanism it is hypothesized that two possible products 38 or
39 could be forming in the reaction (Scheme 18). If the lone pairs on Nitrogen attack on
the carbonyl carbon following the elimination of allyl protecting group would result in 6
membered lactam ring. Due to presence of base, nitrogen can deprotonate and can again
attack on imine carbon center of 21 resulting in product 38. In second case after lactam
ring formation nitrogen can form imine in the same ring by donating electron to carbonyl
carbon and oxygen will attack at imine carbon center of 21 which will result in product 39.

Scheme 18: Proposed unexpected products during the reaction of 35 or 36 with 21
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By doing the HSQC and HMBC analysis and comparing the chemical shift values
with ACD NMR predicted values, it was decided that the product 38 is the most likely
forming in this reaction.
Various conditions were explored for the coupling of ammonium salt 35 or 36
with isothiourea 21 (Table 2). For example, DMF and CHCl3 were used as polar solvents
because starting material was not completely soluble in CH2Cl2. All the conditions did not
give the product 37, but removal of ester suggested the formation of lactam ring type
structure. Since the coupling strategies described above were unsuccessful, it was
concluded that either the type of ester needs to be changed or the coupling conditions
modified, however, time constraints didn’t permit different strategies to be explored.
Table 2: Reaction summary for attempted synthesis of 37 from 35 and 36
Starting

Conditions

Observations

Results

i-Pr2NEt, HgCl2,

No starting

Complex mixture

r.t, 30 min

material

CH2Cl2,

remaining

i-Pr2NEt, HgCl2,

No starting

No product after

r.t, 40 min,

material

workup

CH2Cl2 + DMF

remaining

i-Pr2NEt, HgCl2,

No starting

r.t, 1 h

material

CH2Cl2

remaining

H2O,

Starting material

100 °C, 5h

remaining

i-Pr2NEt,

Complex

H2O, 100 °C, 4 h

mixture

material
21 + 36

21 + 36

21 + 35

21 + 36

21 + 36
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Complex mixture

No product

Complex mixture

21 + 36

Et3N, HgCl2,

S.M, New spots

No product after

r.t to 25 °C

appeared

column

Et3N, HgCl2,

No starting

Complex mixture

r.t to 25 °C

material

CHCl3

remaining

CHCl3
21 + 35

Proposed synthesis of L-Enduracididine 23 from Tces-protected arginine
derivative 14.
It was hypothesized that target molecule 23 would be synthesized from the Tcesprotected arginine 37 by using a Rh catalyst reported by Espino et al. at Stanford
University35 (Scheme 16). As described earlier, they have shown efficient C−H amination
of N-trichloroethoxysulfonyl-protected ureas and guanidines to form 5- and 6-membered
rings. The urea in our synthesis had the same electron withdrawing Tces group so it was
anticipated that reaction should be a success. We used commercial catalyst Rh2(esp)2 for
C-H amination. (Scheme 18)
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Scheme 19: Attempted synthesis of final product 23 via arginine derivative 37

If the successful synthesis of 37 had resulted, it would have represented a new and
efficient method to access derivatives of enduracididine such as 23 via a rhodium-catalyzed
C-H activation reaction.

Exploring the C-H activation of commercially-available arginine derivatives
with Rh2(esp)2.
To demonstrate the ability of Rh2(esp)2 to effect C-H amination on a complex
substrate, it was decided to use a commercially-available arginine derivative having the
guanidine group protected with a different functionality closely related to Tces. For this
purpose, p-toluenesulfonyl (Ts)-protected arginine derivative 40 was chosen. Initially, the
C-H activation reaction was directly attempted on this derivative, however, the polar
carboxylic acid made the purification of the product very challenging. Therefore, it was
decided to protect the carboxyl group as its methyl ester using DCC/DMAP (Scheme 20).
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Scheme 20: Protection of carboxyl group of 40 to form methyl ester 41.

The reaction conditions for synthesizing 41 were followed as described by
Spinnler et al38. 1H NMR and 13C NMR spectroscopy confirmed the identity and purity of
41. A singlet at δ 3.7 ppm in the 1H NMR spectrum corresponds to the three protons of the
OCH3 group and the 13C NMR spectrum indicates the carbon of the OCH3 at δ 52.2 ppm,
confirming the desired methyl ester containing product 41 was obtained.

Scheme 21: Attempted synthesis of 42 from 41 via C-H activation with Rh2(esp)2

The C-H activation reaction for making the 5-membered guanidine ring was
attempted on protected arginine derivative 41 following the conditions of Kim et al.36
(Scheme 18). However, the reaction did not lead to product 42. Consumption of 41 and
formation of a complex mixture was observed. 1H NMR spectroscopic analysis did not
corroborate the formation of the desired product and suggested that loss of the methyl ester
had occurred, as evident by the absence of the expected singlet at δ 3.70 ppm.
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Conclusion and prospective work
The proposed synthesis to obtain several protected arginine derivatives and
consequent cyclization of these molecules leading to the target molecule 23 has proven to
be complex and challenging. The first half of the synthesis pathway was accomplished
successfully in which isothiourea 21 and protected L-ornithine derivatives 30 and 37 were
synthesized. However, the attempted synthesis of protected arginine derivatives by
coupling reaction of 21 with the protected L-ornithine derivatives resulted in formation of
suspected lactam side products. Moreover, C-H amination on 41 to synthesize 42 also did
not work as anticipated.
For future, it would be interesting to make the L-ornithine derivatives by
protecting the carboxyl group with more stable protecting groups and coupling with
isothiourea derivatives that contain electron withdrawing groups other than Tces, which
would help to expand the scope of the C-H amination. It would also be worth further
exploring the scope of Rh2(esp)2 for C-H amination on more complex substates. Of note,
substrate 41 used in our research is more complex than the ones reported by Kim et al.36
for this methodology.
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Chapter 4: Experimental
General procedures
Solvents
Anhydrous solvents such as diethyl ether, dichloromethane, toluene, and
methanol were obtained from an innovative Technology, Inc. Solvent Delivery System
before use and stored over 4 Å molecular sieves. No further purification was needed for
these solvents. Other solvents such as hexanes, ethyl acetate, and ethanol were purchased
as American Chemical Society (ACS) grade from Pharmco (Brookfield, CT), VWR
(Bridgeport, NJ ), MilliporeSigma Chemical Company (St. Louis, MO), and Alfa Aesar
(Haverhill, MA), and used without further purification unless otherwise stated. Deionized
water was obtained from the university water system.
Reagents and reaction conditions
All reagents were purchased from Oakwood Products, Inc. (Estill, SC),
Sigma-Aldrich (St. Louis, MO), AmBeed Inc. (Arlington Hts, IL) unless specifically
stated. All reagents were American Chemical Society (ACS) grade and used without
further purification unless otherwise stated. All reactions involving air or moisture
sensitive reactants and/or requiring anhydrous conditions were performed under a positive
pressure of nitrogen using oven or flame-dried glassware. The removal of solvent in vacuo
refers to evaporation under reduced pressure below or at 40 °C using a Büchi rotary
evaporator followed by evacuation (< 0.1 mm Hg) to a constant sample mass. Brine refers
to a saturated aqueous solution of NaCl.
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Purification techniques
All reactions and fractions from column chromatography were monitored
by thin layer chromatography (TLC) using glass-backed plates (1.5 x 5 cm) pre-coated
(0.25 mm) with silica gel containing a UV fluorescent indicator (normal silica gel, 60 F254)
unless otherwise stated. Compounds were visualized by exposing the plates to UV light, or
by dipping the plates in solutions of potassium permanganate followed by heating on a hot
plate. All the mobile phases were prepared per use and mentioned in their respective
procedures.
Instrumentation for compound characterization
Nuclear Magnetic Resonance (NMR) spectra were measured on a Bruker 500 FTNMR operating at 500 MHz 1H and 126 MHz for 13C NMR spectroscopy, or a Bruker 700
FT-NMR operating at 700 MHz 1H and 176 MHz for 13C spectroscopy. Deuterated solvents
for NMR analysis were purchased from Cambridge Isotope Laboratories and stored over 4
Å molecular sieves. All 1H NMR and 13C NMR chemical shifts are reported in parts per
million (ppm) downfield relative to tetramethylsilane (TMS) as the internal standard while
using the residual proton resonance of solvents as the reference: CDCl3, δ 7.24; (CD3)2SO,
2.50. All

C NMR chemical shifts are described relative to: CDCl3, δ 77.0; (CD3)2SO,
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39.52. 1H NMR data are reported in the following order: multiplicity (s, singlet; d, doublet;
t, triplet; q, quartet; quin, quintet; and m, multiplet, dt, doublet of triplets; ddd, doublets of
doublets of doublets; td, triplet of doublets; qd, quartet of doublets), number of protons,
coupling constant (J) in Hertz (Hz), and assignment. Additional assignments were made
using heteronuclear single quantum coherence (gHSQC), and heteronuclear multiple bond
correlation spectroscopy (gHMBC). When appropriate, the multiplicity is preceded by br,
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implying that the signal was broad. The coupling constants reported are within an error
range of 0.2-0.4 Hz and have been rounded to the nearest 0.1 Hz. All literature compounds
had 1H NMR, and 13C NMR consistent with the assigned structures.

Detailed Experimental Section
2,2,2-Trichloroethylsulfamate (24)

This compound was synthesized by adapting the procedure from Guthikonda et
al.37 Formic acid (0.6 mL, 16mmol) was added to ClSO2NCO (1.4mL) drop wise in an
oven-dried and nitrogen flushed 50 mL round-bottom flask at 0 °C with continuous stirring.
White solid formation was observed with vigorous gas evolution during addition. To the
solid, CH3CN (8.5 mL) was added, and mixture was stirred for 1 h at 0 °C and 12 h at rt.
The reaction mixture was cooled to 0 ˚C and a solution of Cl3CCH2OH (1.07 mL, 11 mmol)
in DMA (8.5 mL) was added dropwise. After stirring for 3 h at rt, the solution was diluted
with Et2O (12.5 mL) and H2O (12.5 mL). The organic layer was washed with H2O (1 x
12.5 mL) and brine (2 x 12.5 mL). The organic layer was dried with MgSO4, and the solvent
was removed in vacuo. The crude product was purified by column chromatography on
silica gel (hexanes/EtOAc, 3:1 to 1:1) to give 24 as a white solid (1.40 g, 57%): Rf = 0.35
(CH2Cl2/EtOAc, 15:1); 1H NMR (700 MHz, CDCl3) δ 5.14 (s, 2H, NH2), 4.70 (s, 2H, CH2);
C NMR (176 MHz, CDCl3) δ 93.2, 78.7.
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S,S-Dimethyl-N-(2,2,2-trichloroethoxysulfonyl)carbonimidodithionate( 25).

This compound was synthesized by modifications in the procedure from Kim et
al.36 2,2,2-Trichloroethylsulfamate (0.257 g, 1.125 mmol) was dissolved in DMF (1.0 mL)
in an oven-dried and nitrogen flushed 25 mL round-bottom flask. The reaction mixture was
cooled to 0 ˚C and with continuous stirring, aqueous NaOH (20 M, 80 mL, 1.57 mmol, 1.4
equiv.) and CS2 (40 mL, 0.67 mmol, 0.6 equiv.) were added sequentially to the solution.
Two additional portions of 20 M NaOH (0.04 mL, 0.787 mmol, 0.7 equiv.) and CS2 (0.02
mL, 0.337 mmol, 0.3 equiv.) were added at 15 min intervals. The solution was stirred at 0
ºC for 20 min and then at rt for 2 h. After 2 h the dark reddish colored solution was cooled
to 0 ºC and Me2SO4 (0.22 mL, 2.36 mmol, 2.1 equiv.) was added dropwise over 8-10 min.
The resulting yellow solution was allowed to warm to rt and stirred for 3 h. H2O (1.5 mL)
was added slowly to the solution. The mixture was cooled to 0 ºC and stirred vigorously
for 1 h. An orange-colored layer settled at the bottom. The organic layer was diluted with
EtOAc (2 mL). The DMF was removed by washing the organic layer with H2O (1 x 3 mL)
and brine (2 x 2 mL). The organic layer was dried with MgSO4, and the solvent was
removed in vacuo. The crude product was purified by column chromatography on silica
gel (hexanes/EtOAc, 4:1) to give 25 as white crystals (0.334 g, 89%): Rf = 0.43
(hexanes/EtOAc, 2:1); 1H NMR (500 MHz, CDCl3) δ 4.75 (s, 2H, CH2), 2.63 (s, 6H, CH3);
C NMR (125 MHz, CDCl3) δ 189.8, 93.3, 79.2, 16.7.
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S-Methyl-N-(2,2,2-trichloroethoxysulfonyl)isothiourea (21).

The compound was prepared by following the procedure from Kim et al.36 S,SDimethyl-N-(2,2,2-trichloroethoxysulfonyl)carbonimidodithionate (0.117 g, 0.35 mmol)
was dissolved in MeOH (400 mL) in an oven-dried and nitrogen flushed 10 mL roundbottom flask, and the solution was heated to 50 ºC. Methanolic NH3 (2 M, 210 mL, 0.42
mmol, 1.2 equiv.) was added dropwise with continuous stirring. The reaction mixture was
stirred at 50 ºC for 1 h. The solution was cooled to 23 ºC and concentrated in vacuo. The
crude product was purified by column chromatography on silica gel (hexanes/EtOAc, 4:1
to 2:1). After evaporating the solvent, the pure product (21) was obtained as a white solid
(0.099 g, 94%): Rf = 0.39 (hexanes/EtOAc, 2:1); 1H NMR (700 MHz, CDCl3) δ 4.69 (s,
2H), 2.48 (s, 3H); 13C NMR (176 MHz, CDCl3) δ 171.7, 93.6, 78.8, 14.2.
N-(δ-tert-Butoxycarbonyl)-N-(α-([fluoren-9-yl]methoxy)carbonyl)-L-ornithine
methyl ester (28).

This compound was synthesized by following the procedure from Spinnler et al.38
Fmoc-Orn(Boc)-OH (0.501 g, 1.1 mmol) was dissolved in CH2Cl2 (12.5 mL) in an ovendried 25 mL round-bottom flask. Methanol (200 mL, 4.4 mmol) and DMAP (15 mg, 0.12
mmol, 0.1 equiv.) were added sequentially to the reaction mixture. The mixture was cooled
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to 0 ˚C. Dicyclohexylcarbodiimide (DCC) (278 mg, 1.35 mmol, 1.23 equiv.) was added
and stirring was continued for 18 h, while allowing the mixture to warm to rt. The white
precipitate was removed by vacuum filtration. The filtrate was diluted with hexane/EtOAc
(1:1, 12 mL) and washed with 2% aqueous NaHSO4 (10 mL), H2O (10 mL), 5% aqueous
K2CO3 (10 mL), H2O (10 mL) and brine (10 mL). The organic layer was dried with
Na2SO4. The solvent was removed in vacuo and the residue was subjected to column
chromatography on silica gel (100% CH2Cl2 to CH2Cl2/EtOAc, 5:1). Evaporation of
solvent gave the desired product (28) as a white solid (0.4115 g, 80%): Rf = 0.5
(CH2Cl2/EtOAc, 5:1); 1H NMR (500 MHz, DMSO-d6) δ 7.90 (d, J = 7.5 Hz, 2H, ArH),
7.78 (d, J = 7.8 Hz, 1H, HN-Fmoc), 7.72 (dd, J = 7.5, 2.4 Hz, 2H, ArH), 7.42 (t, J = 7.5
Hz, 2H, ArH), 7.37 – 7.29 (m, 2H, ArH), 6.80 (t, J = 5.6 Hz, 1H, HNCH2), 4.31 (d, J = 7.5
Hz, 2H, CO2CH2), 4.23 (t, J = 7.5 Hz, 1H, CO2CH2CH), 4.08 – 3.95 (m, 1H, HCNH-Fmoc),
3.62 (s, 3H, OCH3), 2.92 (m, 2H, CH2NH), 1.75 – 1.66 (m, 1H, HaHbCCH-NH), 1.63 –
1.55 (m, 1H, HaHbCCH-NH), 1.49 – 1.40 (m, 2H, CH2CH2NH), 1.38 (s, 9H, OC(CH3)3);
C NMR (125 MHz DMSO-d6) δ 173.3, 156.6, 156.1, 144.3, 141.2, 128.1, 127.5, 125.7,
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120.6, 77.9, 66.1, 54.1, 52.3, 47.1, 33.8, 28.7, 28.5, 26.5.
N-(α-([Fluoren-9-yl]methoxy)carbonyl)-L-ornithine

methyl

ester

hydrotrifluoroacetate (29).

The deprotection was carried out following the procedure from Spinnler et al.38
Trifluoracetic acid (0.43 mL, 5.58 mmol) was added to a stirred solution of 28 (131 mg,
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0.23 mmol) in CH2Cl2 (1.4 mL). The reaction mixture was stirred at rt for 3 h. The solvent
was removed in vacuo. The light-yellow sticky product was further dried under high
vacuum for 18 h, giving product (29) with quantitative yield. 1H NMR (500 MHz, DMSOd6) δ 7.90 (d, J = 7.5 Hz, 2H, ArH), 7.83 (d, J = 8.3 Hz, 1H, HN-Fmoc), 7.71 (dd, J = 7.5,
3.7 Hz, 2H, ArH), 7.68 (br s, 3H, NH3), 7.43 (t, J = 7.5 Hz, 2H, ArH), 7.37 – 7.31 (m, 2H,
ArH), 4.36 (dd, J = 10.6, 6.9 Hz, 1H, CO2CHaHb), 4.30 (dd, J = 10.6, 6.9 Hz, 1H,
CO2CHaHb), 4.23 (t, J = 6.9 Hz, 1H, CO2CH2CH), 4.06 (td, J = 8.3, 4.9 Hz, 1H, CH-NHFmoc), 3.64 (s, 3H, OCH3), 2.84 – 2.72 (m, 2H, CH2NH3), 1.84 – 1.68 (m, 2H, H2CCHNH), 1.64 – 1.57 (m, 2H, CH2CH2NH3); 13C NMR (126 MHz, DMSO-d6) δ 173.0, 158.8,
156.6, 144.2, 141.2, 128.2, 127.6, 125.7, 120.6, 66.1, 55.4, 53.8, 52.5, 47.1, 38.9, 28.0,
24.3.
N-(α-([Fluoren-9-yl]methoxy)carbonyl)-L-ornithine methyl ester hydrochloride (30).

This deprotection was done by modifications in the procedure from Han et al.39
Compound 28 (93.7 mg, 0.2 mmol) was added to HCl in dioxane (4 M, 4 mL) at 0 ˚C in
an oven dried and nitrogen flushed 25 mL round-bottom flask. The flask was removed from
the ice bath and the solution was stirred at rt for 30 min. The mixture was concentrated in
vacuo. The resulting white solid was washed with diethyl ether and the product was dried
under high vacuum to give 30 as a white solid (79 mg, 98%); 1H NMR (700 MHz, DMSOd6) δ 7.90 (d, J = 7.5 Hz, 2H, ArH), 7.88 – 7.80 (m, 4H, NH, NH3), 7.72 (dd, J = 7.5, 4.8
Hz, 2H, ArH), 7.43 (t, J = 7.5 Hz, 2H, ArH), 7.36 – 7.32 (m, 2H, ArH), 4.35 (dd, J = 10.6,
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7.1 Hz, 1H, CO2CHaHb), 4.30 (dd, J = 10.6, 7.1 Hz, 1H, CO2CHaHb), 4.23 (t, J = 7.1 Hz,
1H, CO2CH2CH), 4.07 – 4.02 (m, 1H, CH-NH-Fmoc), 3.64 (s, 3H, OCH3), 2.77 (q, J = 6.1
Hz, 2H, CH2NH3), 1.78 (ddt, J = 14.1, 10.5, 5.3 Hz, 2H, H2CCH-NH), 1.64 – 1.56 (m, 2H,
CH2CH2NH3); 13C NMR (176 MHz, DMSO-d6) δ 173.0, 156.6, 144.2, 141.2, 128.1, 127.6,
125.7, 120.6, 66.8, 53.9, 52.4, 47.1, 38.8, 28.0, 24.3.
N-(δ-tert-Butoxycarbonyl)-N-(α-([fluoren-9-yl]methoxy)carbonyl-L-ornithine

allyl

ester (34).

This compound was synthesized by adapting the procedure from Spinnler et al.38
In an oven-dried 25 mL round-bottom flask, Fmoc-Orn(Boc)-OH (0.5 g, 1.1 mmol) was
dissolved in CH2Cl2 (12.5 mL). Allyl alcohol (0.14 mL, 2.06 mmol, 1.87 equiv.) and
DMAP (16.8 mg, 0.137 mmol, 0.12 equiv.) were added to the reaction mixture
sequentially, which was then cooled to 0 ˚C. DCC (299 mg, 1.45 mmol, 1.32 equiv.) was
added and stirring was continued for 18 h while allowing the mixture to warm to rt. The
white precipitate was removed by vacuum filtration. The filtrate was diluted with
hexane/EtOAc (1:1, 12 mL) and washed with 2% aqueous NaHSO4 (10 mL), H2O (10 mL),
5% aqueous K2CO3 (10 mL), H2O (10 mL) and brine (10 mL). The organic layer was dried
with Na2SO4. The solvent was removed in vacuo and the residue was subjected to column
chromatography on silica gel (CH2Cl2/EtOAc, 5:1). Evaporation of solvent gave 34 as a
white solid (506 mg, 93%): Rf = 0.75 (CH2Cl2/EtOAc, 5:1); 1H NMR (700 MHz, DMSOd6) δ 7.89 (d, J = 7.5 Hz, 2H, ArH), 7.80 (d, J = 7.8 Hz, 1H, HN-Fmoc), 7.74 – 7.69 (m,
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2H, ArH), 7.42 (t, J = 7.5 Hz, 2H, ArH), 7.33 (t, J = 7.5 Hz, 2H, ArH), 6.80 (t, J = 5.7 Hz,
1H, HNCH2), 5.88 (ddt, J = 17.2, 10.6, 5.3 Hz, 1H, H2C=CH), 5.30 (dd, J = 17.2, 1.7 Hz,
1H, HaHbC=CH), 5.19 (dd, J = 10.6, 1.7 Hz, 1H, HaHbC=CH), 4.57 (dt, J = 5.3, 1.7 Hz,
2H, OCH2CH=CH2), 4.30 (dd, J = 7.1, 4.3 Hz, 2H,HNCO2CH2), 4.23 (t, J = 7.1 Hz, 1H,
CO2CH2CH), 4.04 (ddd, J = 9.8, 7.9, 5.0 Hz, 1H, CH-NH-Fmoc), 2.95 – 2.87 (m, 2H,
CH2NH), 1.71 (ddt, J = 14.5, 10.2, 5.1 Hz, 1H, HaHabCH-NH), 1.59 (dtd, J = 14.5, 10.2,
5.1 Hz, 1H, HaHbCCH-NH), 1.50 – 1.42 (m, 2H, CH2CH2NH), 1.37 (s, 9H, OC(CH3)3);
C NMR (176 MHz, DMSO-d6) δ 172.5, 156.6, 156.1, 144.3, 144.2, 141.2, 132.9, 128.1,

13

127.5, 125.7, 120.6, 118.1, 77.9, 66.1, 65.2, 54.2, 47.1, 28.7, 28.4, 26.6.
N-(α-([Fluoren-9-yl]methoxy)carbonyl)-L-ornithine allyl ester hydrochloride (36).

This deprotection was done by modifications in the procedure from Han et al.39
Compound 11 (101 mg, 0.2 mmol) was added to an oven dried and nitrogen flushed 25 mL
round-bottom flask containing HCl in dioxane (4 M, 4 mL) at 0 ˚C. The flask was removed
from the ice bath and the solution was stirred at rt for 1 h. The solution was concentrated
in vacuo. The resulting white solid was washed with diethyl ether and was dried under high
vacuum. Product 36 was collected as a white solid (67.5 mg, 78%); 1H NMR (700 MHz,
DMSO-d6) δ 7.90 (d, J = 7.5 Hz, 2H, ArH), 7.89 – 7.77 (m, 4H, NH, NH3), 7.71 (dd, J =
7.6, 3.4 Hz, 2H, ArH), 7.43 (t, J = 7.4 Hz, 2H, ArH), 7.34 (tdd, J = 7.5, 3.1, 1.1 Hz, 2H,
ArH), 5.89 (ddt, J = 17.2, 10.6, 5.3 Hz, 1H, H2C=CH), 5.32 (dq, J = 17.2, 1.8 Hz, 1H,
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HaHbC=CH), 5.21 (dq, J = 10.5, 1.5 Hz, 1H, HaHbC=CH), 4.59 (dt, J = 5.3, 1.6 Hz, 2H,
OCH2CH=CH2), 4.35 (dd, J = 10.6, 7.0 Hz, 1H, CO2CHaHb), 4.30 (dd, J = 10.6, 7.0 Hz,
1H, CO2CHaHb), 4.23 (t, J = 7.0 Hz, 1H, CO2CH2CH), 4.10 – 4.05 (m, 1H, CH-NH), 2.77
(dp, J = 12.4, 6.3 Hz, 2H, CH2NH3), 1.84 – 1.78 (m, 1H, HaHbCCH-NH), 1.68 (ddd, J =
13.8, 9.4, 4.3 Hz, 1H, HaHbCCH-NH), 1.65 – 1.57 (m, 2H, CH2CH2NH3); 13C NMR (176
MHz, DMSO-d6) δ 172.2, 156.7, 144.2, 141.2, 132.8, 128.1, 127.6, 125.6, 120.6, 118.3,
66.2, 65.4, 54.0, 47.1, 38.8, 28.0, 24.3.
N-(α-([Fluoren-9-yl]methoxy)carbonyl)-L-ornithine allyl ester hydrotrifluoroacetate
(35).

The deprotection was done by modifications in the procedure from Spinnler et
al.38 Trifluoracetic acid (0.5 mL, 6.5 mmol) was added to a stirred solution of 11 (130 mg,
0.28 mmol) in CH2Cl2 (1.4 mL). The reaction mixture was stirred at rt for 1 h. The solvent
was removed in vacuo. The light yellow sticky product 12 was further dried under high
vacuum for 18 h. 1H NMR (700 MHz, DMSO-d6) δ 7.9 (d, J = 7.5 Hz, 2H, ArH), 7.8 (d, J
= 8.0 Hz, 1H, NH-Fmoc), 7.7 (dd, J = 7.5, 3.8 Hz, 3H, NH3), 7.7 (d, J = 7.5 Hz, 2H, ArH),
7.4 (t, J = 7.5 Hz, 2H, ArH), 7.4 – 7.3 (m, 2H, ArH), 5.9 (td, J = 10.7, 5.2 Hz, 1H, H2C=CH),
5.3 (dt, J = 17.3, 1.5 Hz, 1H, HaHbC=CH), 5.2 (dt, J = 10.7, 1.5 Hz, 1H, HaHbC=CH), 4.6
– 4.6 (m, 2H, OCH2CH=CH2), 4.4 (dd, J = 10.6, 7.0 Hz, 1H, CO2CHaHb), 4.3 (dd, J = 10.7,
7.0 Hz, 1H, CO2CHaHb), 4.2 (t, J = 7.0 Hz, 1H, CO2CH2CH), 4.1 (td, J = 9.0, 4.9 Hz, 1H,
CH-NH), 2.8 (p, J = 6.2 Hz, 2H, CH2NH3), 1.8 (dt, J = 8.8, 4.9 Hz, 1H, HaHbCCH-NH),
1.7 (ddd, J = 13.1, 9.4, 4.2 Hz, 1H, HaHbCCH-NH), 1.6 – 1.5 (m, 2H, CH2CH2NH3); 13C
43

NMR (176 MHz, DMSO-d6) δ 172.2, 158.6, 156.7, 144.2, 141.2, 132.8, 128.1, 127.6,
125.7, 125.6, 120.6, 118.3, 66.2, 65.4, 53.9, 47.1, 38.9, 28.0, 24.3.
L-Ornithine, N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N5-[imino[[(4methylphenyl)sulfonyl]amino]methyl]-, methyl ester (41).

This compound was synthesized by modifications in the procedure from Spinnler
et al.38 In an oven-dried 50 mL round-bottom flask, Fmoc-Arg(Tos)-OH (0.601 g, 1.1
mmol) was dissolved in CH2Cl2 (12.5 mL). Methanol (200 mL, 4.4 mmol) and DMAP (15
mg, 0.12 mmol, 0.1 equiv.) were added sequentially to the reaction mixture. The mixture
was cooled to 0 ˚C. DCC (280 mg, 1.36 mmol, 1.24 equiv.) was added and stirring was
continued for 14 h, while allowing the mixture to warm to rt. The white precipitate was
removed by vacuum filtration on celite. The solvent was removed in vacuo and the residue
was subjected to column chromatography on silica gel (CH2Cl2/EtOAc, 1:1 to EtOAc
100% ). Evaporation of solvent gave the desired product 41 as a white solid (601 mg, 97%):
Rf = 0.27 (CH2Cl2/EtOAc, 1:5);1H NMR (700 MHz, CDCl3) δ 7.7 (t, J = 7.7 Hz, 4H, ArH),
7.6 (t, J = 8.8 Hz, 2H, ArH ), 7.4 (dd, J = 9.0, 5.9 Hz, 2H, ArH), 7.3 – 7.3 (m, 2H, ArH),
7.2 (d, J = 7.8 Hz, 2H, ArH), 6.2 (s, 2H, C=NH, SO2NH), 5.6 (s, 1H, CH2NH), 4.4 (d, J =
7.0 Hz, 2H, CO2CH2), 4.3 – 4.2 (m, 1H, HCNH-Fmoc),), 4.2 (t, J = 7.0 Hz, 1H,
CO2CH2CH), 3.7 (s, 3H, OCH3), 3.3 – 3.1 (m, 2H, CH2NH), 2.3 (s, 3H, H3C-Ph), 1.9 (dd,
J = 12.7, 4.1 Hz, 1H, HaHbCCH-NH), 1.9 – 1.8 (m, 1H, HaHbCCH-NH), 1.6 (dd, J = 10.8,
5.1 Hz, 2H, CH2CH2NH); 13C NMR (176 MHz, CDCl3) δ 172.7, 156.8, 156.5, 143.7, 142.0,
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141.3, 129.2, 127.8, 127.1, 126.0, 125.1, 120.0, 67.2, 52.6, 49.2, 47.1, 40.7, 33.9, 25.6,
24.9, 21.4.
N2-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-ornithine hydrochloride (43).

This deprotection was done by modifications in the procedure from Han et al.39
Fmoc-Orn(Boc)-OH (180.6 mg, 0.39 mmol) was added to an oven dried and nitrogen
flushed 25 mL round-bottom flask containing HCl in dioxane (4 M, 6 mL) at 0 ˚C. The
flask was removed from the ice bath and the solution was stirred at rt for 1 h. The solution
was concentrated in vacuo. The resulting white solid was washed with diethyl ether and
was dried under high vacuum. Product 43 was collected as a white solid (156mg, 100%);
1

H NMR (700 MHz, DMSO-d6) δ 12.8 – 12.6 (m, 1H, OH), 7.9 (d, J = 7.5 Hz, 2H, ArH),

7.9 (br s, 3H, NH3), 7.7 (dd, J = 7.5, 3.1 Hz, 2H, ArH), 7.7 (d, J = 8.2 Hz, 1H, HN-Fmoc),
7.4 (t, J = 7.5 Hz, 2H, ArH), 7.3 (td, J = 7.5, 2.3 Hz, 2H, ArH), 4.3 – 4.3 (m, 2H, CO2CH2),
4.2 (t, J = 7.2 Hz, 1H, CO2CH2CH), 4.0 (td, J = 8.5, 4.3 Hz, 1H, CH-NH-Fmoc), 2.8 (p, J
= 5.9 Hz, 2H, CH2NH3), 1.8 – 1.6 (m, 2H, H2CCH-NH), 1.6 (m, 2H, CH2CH2NH3); 13C
NMR (176 MHz, DMSO-d6) δ 174.0, 156.7, 144.3, 141.2, 128.1, 127.6, 125.7, 120.6, 66.8,
53.8, 47.1, 38.9, 28.2, 24.4.
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